CS MEDICA Advances Global Reach with 180˚ Drug Store Alliance, Powered by Pull Market Strategy.
Strategic Alliance Catalyzes Market Penetration with a Potential of 440,000 Units in the First Year.
CS MEDICA A/S, a first mover in integrating CBD into registered substance-based medical devices, announces a strategic partnership with 180˚ Drug Store to penetrate Germany and key markets in the Gulf Cooperation Council (GCC). This initiative is a cornerstone of CS MEDICA's pull strategy, drawing on the demand for its innovative treatments in pain management, autoimmune and stress-related disorders.
Pioneering Innovation and Strategic Market Expansion
In the last two years, CS MEDICA has established a footprint in MedTech, integrating CBD into regulated substance-based medical devices. The company's B2B2C model, characterized by strong R&D and market strategies, has led to empowering partnerships, providing in-depth knowledge about the endocannabinoid system, and fostering patient-centric healthcare solutions that evolve with the industry.
This new partnership with 180˚ Drug Store underscores its mission to alleviate the pain and discomfort associated with the conditions it aims to treat. The channel strategy, i.e., has been a catalyst from Italy, where an own-label partner has already placed four orders within six months, to Australia, where the first paid invoice for production of the CANNASEN® pain patch demonstrates the effectiveness of our new strategy after months of delay in registration.
Pull Strategy Fueling Expansion into New Markets
"Our focus has been on growing the European market, and a pull strategy for emerging markets has been pivotal to our success, reflected in our rapid market gains, now strengthening our access to the German market and extending to the GCC through our partnership with 180˚ Drug Store," says Lone Henriksen, CEO of CS MEDICA.
The CEO of 180˚ Drug Store, Reem Mohammed Salim Ashour, comments, “With our strong background in navigating stringent pharmaceutical regulations, we have been on the lookout for a partner like CS MEDICA. Their ability to merge pharma-grade standards with fewer side effects and innovative formulas is precisely what the market we operate in needs. The proactive demand we're witnessing for CS MEDICA's products not only assures us of their strong market potential but also firmly validates our decision to join forces for our strategic expansion in the GCC."
Strategic Sales Forecast and Regulatory Pathways
The financial model underpinning this alliance is robust and structured, with a 100% prepayment upon registration approval. Anticipated first-year sales, post-approval, are projected at 440,000 units within Germany and the GCC. For the GCC, the compliance process is underway to secure necessary local registrations before initiating production. In contrast, Germany is approved for sale under the EU MDR (Medical Device Regulation) but the launch will run parallel with the GCC go-to-market track as the own-label brand is currently planned as a joint production.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.
180˚ Drug Store is a key player in distributing innovative healthcare products across the GCC. Our expertise in navigating the region's complex regulatory and market landscape is pivotal to introducing state-of-the-art treatments to the market. Born from extensive pharmaceutical manufacturing and distribution experience, we position ourselves as a forward-thinking player in the pharmaceutical landscape.
Tags: